Nyström Lennarth, Bjurstam Nils, Jonsson Håkan, Zackrisson Sophia, Frisell Jan
1 Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
2 Department of Radiology, Sahlgrenska University Hospital, Sahlgrenska Academy, Göteborg, Sweden.
J Med Screen. 2017 Mar;24(1):34-42. doi: 10.1177/0969141316648987. Epub 2016 Jul 7.
Objective To analyze the age- and trial-specific effects of the breast cancer screening trials with mammography in Malmö, Stockholm, and Göteborg. Methods The original trial files were linked to the Swedish Cancer and Cause of Death Registers to obtain date of breast cancer diagnosis and date and cause of death. Relative risks and 95% confidence intervals were calculated using the evaluation model (only breast cancers diagnosed between date of randomization and date when the first screening round of the control group was completed were included in the analysis). Results Women aged 40-70 at randomization in the Malmö I and II, Stockholm, and Göteborg trials were followed-up for an average of 30, 22, 25, and 24 years, respectively. The overview of all trials resulted in a significant decrease of 15% in breast cancer mortality. The variation by consecutive 10-year age group at randomization was small-from 21% in the age group 40-49 to 11% in the age group 50-59. After adjustment for age, there was a significant reduction in breast cancer mortality in the Göteborg trial (26%), and a non-significant reduction in the Malmö I and II and Stockholm trials (12%, 15%, and 5.8%, respectively). Conclusions The overview showed a 15% significant relative reduction in breast cancer mortality due to invitation to mammography screening. Heterogeneity in age, trial time, attendance rates, and length of screening intervals may have contributed to the variation in effect between the trials.
目的 分析马尔默、斯德哥尔摩和哥德堡进行的乳腺钼靶乳腺癌筛查试验的年龄和试验特异性效应。方法 将原始试验文件与瑞典癌症和死亡原因登记册相链接,以获取乳腺癌诊断日期、死亡日期和死亡原因。使用评估模型计算相对风险和95%置信区间(分析仅纳入随机分组日期至对照组第一轮筛查完成日期之间诊断出的乳腺癌)。结果 在马尔默I和II、斯德哥尔摩和哥德堡试验中,随机分组时年龄在40 - 70岁的女性分别平均随访了30年、22年、25年和24年。所有试验的总体结果显示乳腺癌死亡率显著降低了15%。随机分组时按连续10岁年龄组划分的差异较小——从40 - 49岁年龄组的21%到50 - 59岁年龄组的11%。在对年龄进行调整后,哥德堡试验中的乳腺癌死亡率显著降低(26%),而马尔默I和II以及斯德哥尔摩试验中的降低不显著(分别为12%、15%和5.8%)。结论 总体情况显示,由于接受乳腺钼靶筛查邀请,乳腺癌死亡率相对显著降低了15%。年龄、试验时间、参与率和筛查间隔时间的异质性可能导致了各试验之间效应的差异。